{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:54:20Z","timestamp":1778172860215,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001663","name":"Volkswagen Foundation","doi-asserted-by":"publisher","award":["Niedersachsen Vorab"],"award-info":[{"award-number":["Niedersachsen Vorab"]}],"id":[{"id":"10.13039\/501100001663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Intravitreal injections are a mandatory treatment for macular edema due to nAMD, DME and RVO. These chronic diseases usually need chronic treatment using intravitreal injections with anti-VEGF agents. Thus, many trials were performed to define the best treatment interval using pro re nata regimes (PRN), fixed regimes or treat-and-extend regimes (TE). However, real-world studies reveal a high rate of losing patients within a 2-year interval of treatment observation causing worse results. In this study we analyzed retrospectively 2\u00a0years of real-world experience with an individualized treat-and-extend injection scheme.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Since 2015 our treatment scheme for intravitreal injections has been switched from PRN to TE. Out of 102 patients 59 completed a follow up time of 2\u00a0years. Every patient received visual acuity testing, SD-OCT and slit lamp examination prior to every injection. At each visit an injection was performed and the treatment interval was adjusted mainly on SD-OCT based morphologic changes by increasing or reducing in 2-week steps. Individual changes of the treatment protocol by face-to-face communication between physician and patient were possible.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>After 1\u00a0year of treatment visual acuity gain in nAMD was 7.4\u2009\u00b1\u20092.2 ETDRS letters (<jats:italic>n<\/jats:italic>\u00a0=\u200934; injection frequency: 7.4\u2009\u00b1\u20090.4) respectively 6.1\u2009\u00b1\u20094.7 in DME (<jats:italic>n<\/jats:italic>\u00a0=\u20099; injection frequency: 8.4\u2009\u00b1\u20091.1) and 9.7\u2009\u00b1\u20094.5 in RVO (<jats:italic>n<\/jats:italic>\u00a0=\u200916; injection frequency: 7.6\u2009\u00b1\u20090.5). After 2\u00a0years of treatment results were as following: nAMD: visual acuity gain 6.9\u2009\u00b1\u20092.1 (injection frequency: 12.6\u2009\u00b1\u20090.7); DME: 11.1\u2009\u00b1\u20095.1 (injection frequency: 14.0\u2009\u00b1\u20091.0); RVO: 7.5\u2009\u00b1\u20095.0 (injection frequency: 11.2\u2009\u00b1\u20090.9). Planned treatment exit after 2\u00a0year was achieved in 29.4% of patients in nAMD (0% after 1\u00a0year); 0% in DME (0% after 1\u00a0year); and 31.3% in RVO (0% after 1\u00a0year). Patients\u2019 persistence was 94.1% during the follow-up.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Using a consequent and individualized TE regime in daily practice may lead to a high patients\u2019 persistence and visual acuity gains nearly comparable to those of large prospective clinical trials. Crucial factors are face-to-face communication with the patient as well as a stringent management regime. At this time TE may be the only instrument for proactive therapy which should therefore be regarded as a first-line tool in daily practice.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12886-020-01397-x","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T11:03:04Z","timestamp":1585566184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients\u2019 persistence"],"prefix":"10.1186","volume":"20","author":[{"given":"Ingo","family":"Volkmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Knoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mareile","family":"Wiezorrek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Greb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Framme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"key":"1397_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1001\/archopht.116.5.653","volume":"116","author":"CC Klaver","year":"1998","unstructured":"Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol (Chicago, Ill 1960). 1998;116:653\u20138 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9596502.","journal-title":"Arch Ophthalmol (Chicago, Ill 1960)"},{"key":"1397_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344. https:\/\/doi.org\/10.1056\/NEJMoa062655.","journal-title":"N Engl J Med"},{"key":"1397_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331. https:\/\/doi.org\/10.1056\/NEJMoa054481.","journal-title":"N Engl J Med"},{"key":"1397_CR4","doi-asserted-by":"publisher","first-page":"e78538","DOI":"10.1371\/journal.pone.0078538","volume":"8","author":"A Pielen","year":"2013","unstructured":"Pielen A, Feltgen N, Isserstedt C, Callizo J, Junker B, Schmucker C. Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One. 2013;8:e78538. https:\/\/doi.org\/10.1371\/journal.pone.0078538.","journal-title":"PLoS One"},{"key":"1397_CR5","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006.","journal-title":"Ophthalmology"},{"key":"1397_CR6","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s13300-018-0513-2","volume":"9","author":"F Ziemssen","year":"2018","unstructured":"Ziemssen F, Wachtlin J, Kuehlewein L, Gamulescu M-A, Bertelmann T, Feucht N, et al. Intravitreal Ranibizumab therapy for diabetic macular edema in routine practice: two-year real-life data from a non-interventional, Multicenter Study in Germany. Diabetes Ther. 2018;9:2271\u201389. https:\/\/doi.org\/10.1007\/s13300-018-0513-2.","journal-title":"Diabetes Ther"},{"key":"1397_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305327.","journal-title":"Br J Ophthalmol"},{"key":"1397_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.oret.2017.09.017","volume":"2","author":"C Framme","year":"2018","unstructured":"Framme C, Eter N, Hamacher T, Hasanbasic Z, Jochmann C, Johnson KT, et al. Aflibercept for patients with Neovascular age-related macular degeneration in routine clinical practice in Germany. Ophthalmol Retin. 2018;2:539\u201349. https:\/\/doi.org\/10.1016\/j.oret.2017.09.017.","journal-title":"Ophthalmol Retin"},{"key":"1397_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1755-3768.2012.02493.x","volume":"91","author":"RP Finger","year":"2013","unstructured":"Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol. 2013;91:540\u20136. https:\/\/doi.org\/10.1111\/j.1755-3768.2012.02493.x.","journal-title":"Acta Ophthalmol"},{"key":"1397_CR10","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1755-3768.2012.02457.x","volume":"91","author":"C Lala","year":"2013","unstructured":"Lala C, Framme C, Wolf-Schnurrbusch UEK, Wolf S. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration. Acta Ophthalmol. 2013;91:526\u201330. https:\/\/doi.org\/10.1111\/j.1755-3768.2012.02457.x.","journal-title":"Acta Ophthalmol"},{"key":"1397_CR11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00417-012-2090-9","volume":"251","author":"I Mantel","year":"2013","unstructured":"Mantel I, Deli A, Iglesias K, Ambresin A. Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013;251:697\u2013704. https:\/\/doi.org\/10.1007\/s00417-012-2090-9.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1397_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000452929","volume":"236","author":"H Giannakaki-Zimmermann","year":"2016","unstructured":"Giannakaki-Zimmermann H, Ebneter A, Munk MR, Wolf S, Zinkernagel MS. Outcomes when switching from a pro re nata regimen to a treat and extend regimen using Aflibercept in Neovascular age-related macular degeneration. Ophthalmologica. 2016;236:201\u20136. https:\/\/doi.org\/10.1159\/000452929.","journal-title":"Ophthalmologica"},{"key":"1397_CR13","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.022.","journal-title":"Ophthalmology."},{"key":"1397_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789\u2013801. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.039.","journal-title":"Ophthalmology"},{"key":"1397_CR15","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"J-F Korobelnik","year":"2014","unstructured":"Korobelnik J-F, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247\u201354. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.006.","journal-title":"Ophthalmology"},{"key":"1397_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","volume":"155","author":"DM Brown","year":"2013","unstructured":"Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155:429\u2013437.e7. https:\/\/doi.org\/10.1016\/j.ajo.2012.09.026.","journal-title":"Am J Ophthalmol"},{"key":"1397_CR17","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.2147\/OPTH.S140665","volume":"11","author":"A Pielen","year":"2017","unstructured":"Pielen A, Clark WL, Boyer DS, Ogura Y, Holz FG, Korobelnik J-F, et al. Integrated results from the COPERNICUS and GALILEO studies. Clin Ophthalmol. 2017;11:1533\u201340. https:\/\/doi.org\/10.2147\/OPTH.S140665.","journal-title":"Clin Ophthalmol"},{"key":"1397_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","volume":"121","author":"J-F Korobelnik","year":"2014","unstructured":"Korobelnik J-F, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, et al. Intravitreal Aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology. 2014;121:202\u20138. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.012.","journal-title":"Ophthalmology"},{"key":"1397_CR19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ophtha.2006.10.045","volume":"114","author":"DS Boyer","year":"2007","unstructured":"Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246\u201352. https:\/\/doi.org\/10.1016\/j.ophtha.2006.10.045.","journal-title":"Ophthalmology"},{"key":"1397_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193\u2013201. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.011.","journal-title":"Ophthalmology."},{"key":"1397_CR21","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ, et al. Morphology and visual acuity in Aflibercept and Ranibizumab therapy for Neovascular age-related macular degeneration in the VIEW trials. Ophthalmology. 2016;123:1521\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2016.03.037.","journal-title":"Ophthalmology."},{"key":"1397_CR22","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","volume":"118","author":"U Schmidt-Erfurth","year":"2011","unstructured":"Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik J-F, Schlingemann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118:831\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2010.09.004.","journal-title":"Ophthalmology."},{"key":"1397_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","volume":"118","author":"FG Holz","year":"2011","unstructured":"Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663\u201371. https:\/\/doi.org\/10.1016\/j.ophtha.2010.12.019.","journal-title":"Ophthalmology."},{"key":"1397_CR24","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","volume":"116","author":"DS Boyer","year":"2009","unstructured":"Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116:1731\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2009.05.024.","journal-title":"Ophthalmology"},{"key":"1397_CR25","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2337\/dc10-0493","volume":"33","author":"P Massin","year":"2010","unstructured":"Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399\u2013405. https:\/\/doi.org\/10.2337\/dc10-0493.","journal-title":"Diabetes Care"},{"key":"1397_CR26","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","volume":"118","author":"P Mitchell","year":"2011","unstructured":"Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615\u201325. https:\/\/doi.org\/10.1016\/j.ophtha.2011.01.031.","journal-title":"Ophthalmology."},{"key":"1397_CR27","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124\u20131133.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.022.","journal-title":"Ophthalmology"},{"key":"1397_CR28","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102\u20131112.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.021.","journal-title":"Ophthalmology"},{"key":"1397_CR29","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1016\/j.ophtha.2014.06.011","volume":"121","author":"PA Campochiaro","year":"2014","unstructured":"Campochiaro PA, Wykoff CC, Singer M, Johnson R, Marcus D, Yau L, et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology. 2014;121:2432\u201342. https:\/\/doi.org\/10.1016\/j.ophtha.2014.06.011.","journal-title":"Ophthalmology."},{"key":"1397_CR30","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904\u201314. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.024.","journal-title":"Ophthalmology."},{"key":"1397_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","volume":"121","author":"PA Campochiaro","year":"2014","unstructured":"Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121:209\u201319. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.038.","journal-title":"Ophthalmology."},{"key":"1397_CR32","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","volume":"119","author":"MA Singer","year":"2012","unstructured":"Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175\u201383. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.016.","journal-title":"Ophthalmology."},{"key":"1397_CR33","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.005.","journal-title":"Ophthalmology."},{"key":"1397_CR34","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.1111\/aos.12600","volume":"93","author":"K Januschowski","year":"2015","unstructured":"Januschowski K, Dimopoulos S, Szurman P, Feltgen N, Spitzer B, Pielen A, et al. Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicenter study. Acta Ophthalmol. 2015;93:e400\u20132. https:\/\/doi.org\/10.1111\/aos.12600.","journal-title":"Acta Ophthalmol"},{"key":"1397_CR35","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1136\/bjophthalmol-2015-307249","volume":"100","author":"C Pr\u00fcnte","year":"2016","unstructured":"Pr\u00fcnte C, Fajnkuchen F, Mahmood S, Ricci F, Hatz K, Studni\u010dka J, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016;100:787\u201395. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307249.","journal-title":"Br J Ophthalmol"},{"key":"1397_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","volume":"125","author":"R Silva","year":"2018","unstructured":"Silva R, Berta A, Larsen M, Macfadden W, Feller C, Mon\u00e9s J, et al. Treat-and-extend versus monthly regimen in Neovascular age-related macular degeneration: results with Ranibizumab from the TREND study. Ophthalmology. 2018;125:57\u201365. https:\/\/doi.org\/10.1016\/j.ophtha.2017.07.014.","journal-title":"Ophthalmology."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01397-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-020-01397-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01397-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T23:23:02Z","timestamp":1617060182000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01397-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1397"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01397-x","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,30]]},"assertion":[{"value":"20 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study contains a retrospective analysis of perioperative data. In accordance with our local ethics committee, no ethical approval for retrospective analized data was needed (Ethics Committee, Hannover Medical School, Hannover, Germany).Written informed consent for usage of medical data was obtained from all individual participants included in the study. No procedures on human participants were performed due to study reasons.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The main data in this document does not contain individual data values but only pooled, retrospectively analyzed data. The patient belonging to the individual images shown in Fig.  agreed to use his individual data and images. This agreement is available upon request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CF: Research funding: Novartis; Consultant: Bayer, Zeiss, MedUpdate; Lecturer Fees: Novartis, Bayer, Zeiss, Heidelberg Engineering, Allergan, MedUpdate.The other authors state that there are no potential conflicts of interest in relation to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}